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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. Significantly new data have been published on laryngeal cancer management since the last
edition of the guidelines. This paper discusses the evidence base pertaining to the management of laryngeal
cancer and provides updated recommendations on management for this group of patients receiving cancer care.
Recommendations
• Radiotherapy (RT) and transoral laser microsurgery (TLM) are accepted treatment options for T1a–T2a glottic
carcinoma. (R)
• Open partial surgery may have a role in the management of selected tumours. (R)
• Radiotherapy, TLM and transoral robotic surgery are reasonable treatment options for T1–T2 supraglottic
carcinoma. (R)
• Supraglottic laryngectomy may have a role in the management of selected tumours. (R)
• Most patients with T2b–T3 glottic cancers are suitable for non-surgical larynx preservation therapies. (R)
• Concurrent chemoradiotherapy should be regarded as the standard of care for non-surgical management. (R)
• Subject to the availability of appropriate surgical expertise and multi-disciplinary rehabilitation services, TLM
or open partial surgical procedures ± post-operative RT, may be also be appropriate in selected cases. (R)
• In the absence of clinical or radiological evidence of nodal disease, elective treatment (RT or surgery ± post-
operative RT) is recommended to at least lymph node levels II, III and IV bilaterally. In node positive disease, it
is recommended that lymph node levels II–V should be treated on the involved side. If level II nodes are
involved, then elective irradiation of ipsilateral level Ib nodes may be considered. (R)
• Most patients with T3 supraglottic cancers are suitable for non-surgical larynx preservation therapies. (R)
• Concurrent chemoradiotherapy should be regarded as the standard of care for non-surgical management. (R)
• Subject to the availability of appropriate surgical expertise and multi-disciplinary rehabilitation services, TLM
or open partial surgical procedures ± post-operative RT, may also be appropriate in selected cases. (R)
• In the absence of clinical or radiological evidence of nodal disease, elective treatment (RT or surgery ± post-
operative RT) is recommended to at least lymph node levels II, III and IV bilaterally. In node positive disease,
lymph node levels II–V should be treated on the involved side. (R)
• As per the PET-Neck clinical trial, patients with N2 or N3 neck disease who undergo treatment with
chemoradiotherapy to their laryngeal primary and experience a complete response with a subsequent
negative post-treatment positron emission tomography combined with computed tomography (PET–CT)
scan do not require an elective neck dissection. In contrast, patients who have a partial response to
treatment or have increased uptake on a post-treatment PET–CT scan should have a neck dissection. (R)
• Larynx preservation with concurrent chemoradiotherapy should be considered for T4 tumours, unless there is
tumour invasion through cartilage into the soft tissues of the neck, in which case total laryngectomy yields
better outcomes. (R)
• In the absence of clinical or radiological evidence of nodal disease, elective treatment (RT or surgery ± post-
operative RT) is recommended to bilateral lymph node levels II, III, IV, V and VI. (R)
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Introduction
The aim of any clinician involved in the treatment of
laryngeal squamous cell carcinoma should be to cure
the disease whilst maintaining maximal laryngeal func-
tion. Whilst this seems a simple concept, deciding how
best to achieve this aim in any given patient is often dif-
ficult and results in well-rehearsed complex discussions
within multi-disciplinary team (MDT) meetings
throughout the UK on a regular basis. Underpinning
this lack of clinical certainty is a lack of level I evi-
dence, particularly with respect to the comparative
merits of surgical and non-surgical treatment modal-
ities. Thus, for most laryngeal tumours, perceived treat-
ment equipoise exists. In light of this dearth of good
quality comparative data, what treatment any given
patient receives is typically related to local MDT
dynamics and clinical resources.
Although we are unable to rectify this lack of evi-
dence, in this document we highlight the treatment
options available for any given tumour and attempt,
based on published evidence, to highlight the relative
merits or disadvantages of each approach.
During 2011, 2360 patients were diagnosed with laryn-
geal carcinoma in the UK. Of these, 1506, 108, 245 and
73 were diagnosed in England, Wales, Scotland and
Northern Ireland, respectively. Accordingly, European
Age Standardised Rates per 100 000 for England,
Wales, Scotland and Northern Ireland are 2.7, 3.0, 4.2
and 4.3, respectively; highlighting the fact that larynx
cancer is more common in Wales, Scotland and
Northern Ireland. For the UK as a whole, 1932 (82 per
cent) cases occurred in men and 428 (18 per cent) in
women (M:F; 4.5:1). Larynx cancer accounts for 1 per
cent of all cancers in men and 0.3 per cent of all
cancers in women. However, this amounts to a 22 per
cent reduction of cases diagnosed in men when compar-
ing 1992–1994 with 2009–2011. A comparable reduc-
tion (19 per cent) has occurred in women over this
timeframe. (http://info.cancerresearchuk.org/cancer-
stats/types/larynx) in keeping with the geographical
variation in incidence, larynx cancer is more commonly
diagnosed in patients of lower socio-economic groups.1
It is well documented that alcohol and tobacco, sep-
arately and synergistically are the main causes of larynx
cancer. However, in contrast to oropharynx cancer, it
appears that human papilloma virus infection is not a
major cause.2
Larynx cancer is rare in patients younger than 40
years of age, with incidence increasing with age, rising
to a peak in the eighth decade. Three-quarters of all diag-
noses occur in patients older than 60 years. (http://info.
cancerresearchuk.org/cancerstats/types/larynx)
In 2012, 618 men (79 per cent) and 166 women (21
per cent) died of larynx cancer (M:F; 3.7:1). This con-
stitutes a marked decrease – 25 and 16 per cent,
respectively – in age-standardised mortality for men
and women over the last decade. (http://info.cancerre-
searchuk.org/cancerstats/types/larynx)
However, Rachet et al.1 previously demonstrated a
startling differential mortality rate between socio-eco-
nomic groups, with patients from lower socio-econom-
ic groups suffering higher death rates from larynx
cancer than those from higher socio-economic groups.
Clinical presentation
The clinical presentation of laryngeal cancer is highly
variable and depends on the site and size of the
primary tumour. Tumours of the glottis, for example,
typically present at an early stage as they manifest as
hoarseness. In comparison, tumours of the supraglottis
are likely to present later with symptoms of pain,
hoarseness or swallowing difficulty. However, it is
not uncommon for patients presenting with laryngeal
cancer to delay seeking medical advice on developing
‘early’ symptoms, only to present at a much later
stage with symptoms of pain, swallowing difficulty, a
palpable neck mass or even, in extreme cases, with
airway compromise.
Assessment and staging
As with all head and neck cancers, diagnosis of laryn-
geal cancer relies initially on good history taking and
clinical examination in the clinic. Laryngeal cancers
are, in most cases, obvious following inspection of
the larynx with a fibreoptic laryngoscope in the out-
patient department. Initial assessment of the tumour
stage relies on imaging. Whilst exact protocols vary
according to local imaging preferences, it is typical
for patients suspected of having laryngeal cancer to
undergo either magnetic resonance imaging or com-
puted tomography (CT) of the head and neck and CT
scan of the thorax and upper abdomen. The exception
to this is in patients presenting with the early stage,
T1 lesions of the glottis without anterior commissure
involvement, where imaging is unhelpful. Definitive
diagnosis is achieved by histological examination of a
tissue biopsy, obtained usually at the time of a general
anaesthetic endoscopic examination of the larynx,
pharynx and upper oesophagus. The examination
under anaesthesia is extremely important for staging
and should routinely involve inspection with rigid
(plane 0° and angled 30° and/or 70°) fibreoptic endo-
scopes. The aggregate information provided by the
imaging and the endoscopic examination facilitates the
staging of the tumour according to the tumour–node–
metastasis (TNM) system outlined below (Table I). It
is by recourse to the TNM stage of the tumour, in add-
ition to the general fitness of the patient, that treatment
decisions are ultimately made.
Management
Early (T1–T2a) glottic carcinoma
Early laryngeal cancer (T1–T2a N0 M0) is charac-
terised by low tumour volume and a low incidence of
metastatic neck disease. Consequently, the chances of
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cure are extremely good whichever of the main treat-
ment options – radiotherapy (RT), transoral laser
microsurgery (TLM) or open partial laryngeal
surgery – is employed. A systemic review3 has con-
firmed there is insufficient evidence to determine
which of these three treatment options is most effective
for the treatment of early glottic carcinoma.
Radiotherapy with surgery in reserve or TLM are the
two most commonly used treatment modalities in the
UK. Whilst survival outcomes and local control rates
are similar,4 they have not been compared in rando-
mised trials. Individual treatment selection depends
on patient and tumour factors (e.g. indistinct tumours
diffusely infiltrating the vocal fold mucosa and larger
volume tumours involving the anterior commissure
may be more suitable for RT than transoral laser
surgery) and local expertise. Single-modality treatment
is sufficient and combining surgery with RT should be
avoided as functional outcomes (and perhaps survival
in the context of incompletely resected tumour) may
be compromised by combined-modality therapy.
Radiotherapy is delivered using megavoltage photons
from a linear accelerator (typical energies 4–6 MV);
hypofractionated RT schedules, using a fraction size
greater than 2 Gray (Gy), results in equivalent out-
comes to longer schedules, without increased toxicity.
Typical schedules include 50–52 Gy in 16 fractions
and 53–55 Gy in 20 fractions over three to four
weeks.5 Elective treatment of the neck is not recom-
mended because of the very low risk of occult nodal
disease. Radiotherapy results in significant acute
toxicity, including thick, sticky secretions, hoarse
voice, odynophagia and skin reactions. Most of these
effects resolve four to six weeks after the completion
of treatment and significant late effects are rare.
Should tumour recurrence occur, partial laryngeal
surgery provides a salvage option in appropriate clinic-
al settings, resulting in good oncological and functional
outcomes. However, these techniques are rarely offered
in the UK and, therefore, total laryngectomy is most
commonly performed.
Transoral laser microsurgery is usually undertaken
using a CO2 laser as a day case procedure and has
minimal acute morbidity. Whilst there is equipoise
with respect to voice outcome between RT and TLM
for smaller tumours, long-term quality of voice for
T2 glottic cancers is generally accepted to be better
after RT than after TLM. Voice outcome following
TLM is dependent on the extent of the resection and/
or whether the resection includes the anterior commis-
sure.4 Certain patient factors, may preclude TLM, such
as restriction of neck movement and difficult access. In
these patients, hypofractionated RT is the preferred
option.
Contrary to the practice in other countries, in the UK,
partial open surgical procedures are used less commonly
for the treatment of early de novo glottic carcinoma.
However, they provide an option for the treatment of
de novo tumours which are not accessible to TLM and
for recurrent tumours after TLM or RT. Meta-analysis
data show similar rates of local control and survival
after partial laryngectomy (comparable with TLM and
TABLE I
TNM STAGING SYSTEM FOR LARYNGEAL CANCER
Supraglottis
T1 Tumour limited to one subsite of supraglottis with normal vocal fold mobility
T2 Tumour invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside the supraglottis
(e.g. mucosa of base of tongue, vallecula, medial wall of piriform sinus) without fixation of the larynx
T3 Tumour limited to larynx with vocal fold fixation and/or invades any of the following: post-cricoid area,
pre-epiglottic tissues, paraglottic space, and/or with minor thyroid cartilage erosion (e.g. inner cortex)
T4a Tumour invades through the thyroid cartilage and/or invades tissues beyond the larynx, e.g. trachea,
soft tissues of neck, including deep/extrinsic muscle of tongue (e.g. genioglossus, hyoglossus, palatoglossus
and styloglossus), strap muscles, thyroid and oesophagus
T4b Tumour invades pre-vertebral space, mediastinal structures or encases carotid artery
Glottis
T1 Tumour limited to vocal fold(s) (may involve anterior or posterior commissure) with normal mobility
T1a. Tumour limited to one vocal fold
T1b. Tumour involves both vocal folds
T2 T2a. Tumour extends to supraglottis and/or subglottis with normal vocal fold mobility
T2b. Tumour extends to supraglottis and/or subglottis with impaired vocal fold mobility
T3 Tumour limited to larynx with vocal fold fixation and/or invades paraglottic space, and/or with minor
thyroid cartilage erosion (e.g. inner cortex)
T4a Tumour invades through the thyroid cartilage or invades tissues beyond the larynx, e.g. trachea, soft tissues of neck,
including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus and styloglossus),
strap muscles, thyroid and oesophagus
T4b Tumour invades prevertebral space, mediastinal structures or encases carotid artery
Subglottis
T1 Tumour limited to subglottis
T2 Tumour extends to vocal fold(s) with normal or impaired mobility
T3 Tumour limited to larynx with vocal fold fixation
T4a Tumour invades through cricoid or thyroid cartilage and/or invades tissues beyond the larynx, e.g., trachea,
soft tissues of neck including deep/extrinsic muscle of tongue (genioglossus, hyoglossus, palatoglossus and
styloglossus), strap muscles, thyroid and oesophagus
T4b Tumour invades prevertebral space, mediastinal structures or encases carotid artery
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RT) with larynx preservation rates of 98.3 per cent for de
novo tumours and 84.6 per cent for radio-recurrent
tumours.6,7 Open surgical procedures include laryngo-
fissure cordectomy, vertical partial laryngectomy
(VPL)± reconstruction, frontolateral vertical partial lar-
yngectomy, supraglottic laryngectomy, supracricoid
partial laryngectomy plus cricohyoidoepiglottopexy or
cricohyoidopexy reconstruction (SCPL–CHEP or
CHP) and extended supraglottic laryngectomy.
Overall, for T1a glottic tumours the local control is
similar between RT and TLM (five-year local control
rate 90–93 per cent). In the case of T1b disease, the
local control rate is lower (85–89 per cent).
Similarly, the local control and overall survival rates
for T2a glottic cancers are comparable when treated
with TLM, partial laryngeal resection or RT.
Recommendations
• Radiotherapy and transoral laser
microsurgery are accepted treatment options
for T1a–T2a glottic carcinoma (R)
• Open partial surgery may have a role in the
management of selected tumours (R)
T1–T2 supraglottic cancers
Radiotherapy, TLM and transoral robotic surgery
(TORS) are valid treatment options for all patients
with T1–T2 supraglottic cancers. As with glottic car-
cinomas, open partial surgical procedures (supraglottic
laryngectomy) are used less commonly in the UK but
open supraglottic laryngectomy may have a role in
selected cases in units with appropriate surgical expert-
ise and multi-disciplinary support services. Survival
outcomes appear to be similar with RT and surgery
although, once again, there are no randomised com-
parative data. Whilst long-term functional (voice and
swallowing) outcomes appear similar, early swallow-
ing function is usually poorer after surgery: swallowing
rehabilitation may be prolonged and in a small propor-
tion of patients, adequate swallowing function may
never be achieved. Consequently, patient selection,
based on tumour burden and performance status, is
imperative. Again, every effort should be made to
avoid combining surgery with RT because functional
outcomes may be compromised by combined-modality
therapy.
The supraglottis has a rich lymphatic supply and, as
a consequence, the risk of nodal disease is significantly
higher for T1–T2 supraglottic cancers than for T1–T2
glottic cancers. Thus, even in the absence of clinical or
radiological evidence of nodal involvement, elective
treatment of at least bilateral lymph node levels II and
III – either with RT or selective neck dissection – is
recommended.
Whilst RT or surgery alone, is sufficient for the treat-
ment of node negative T1–T2 supraglottic cancers,
concurrent platinum-based chemoradiotherapy or
surgery followed by post-operative RT is recom-
mended for node positive supraglottic carcinoma
(T1–T2 N1+, stage III–IV) in patients whose perform-
ance status is sufficient to tolerate this treatment. The
role of induction chemotherapy prior to chemora-
diotherapy or surgery remains unclear but may be
appropriate for patients presenting with advanced
nodal disease (e.g. N2c/N3), particularly if this is
rapidly progressive and/or symptomatic.
All treatment options appear to effect similar loco-
regional control and survival rates: For T1 disease,
five-year local control rates following treatment with
RT, TLM, TORS or open supraglottic laryngectomy
range from 77 to 100 per cent. For T2 tumours, the
five-year local control rates range from 80 to 97 per
cent for TLM or open supraglottic laryngectomy and
from 62 to 83 per cent for primary RT.8
Recommendations
• Radiotherapy, transoral laser microsurgery
and transoral robotic surgery are reasonable
treatment options for T1–T2 supraglottic
carcinoma (R)
• Supraglottic laryngectomy may have a role in
the management of selected tumours (R)
T2b–T3 glottic tumours
Most patients with T2b–T3 glottic cancers are suitable
for radiation-based larynx preservation therapy.
However, subject to the availability of appropriate
surgical expertise and multi-disciplinary rehabilitation
services, TLM or open partial surgical procedures ±
post-operative RT, may also be appropriate in selected
cases. Open partial surgical procedures which might be
considered include VPL± reconstruction, frontolateral
VPL, supraglottic laryngectomy, SCPL–CHEP or CHP
and extended supraglottic laryngectomy. In the absence
of clinical or radiological evidence of nodal disease,
elective treatment (RT or surgery ± post-operative
RT) is recommended to at least lymph node levels II,
III and IV bilaterally, because of the risk of occult
nodal metastasis. Intensity-modulated radiotherapy
(IMRT) allows a convenient solution to elective
nodal treatment, enabling differential doses of RT to
be given to different nodal groups simultaneously,
depending on the presence or absence of macroscopic
disease and the risk of subclinical disease.
In node positive disease, it is recommended that
lymph node levels II-V should be treated on the
involved side. If level II nodes are involved, then elect-
ive irradiation of ipsilateral level Ib nodes may be
considered.
The potential of RT and chemotherapy for larynx
preservation was established by the landmark
Veterans Affairs Laryngeal Cancer Study Group
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(VALCSG) study9 in which induction chemotherapy
and RT (IC+RT) yielded similar overall survival (68
per cent at two years) to laryngectomy followed by
adjuvant RT for stage III–IV laryngeal cancer with
high rates of larynx preservation (64 per cent at two
years). Rates of salvage laryngectomy were significant-
ly lower for T3 vs T4 disease (29 per cent vs 56 per cent,
p= 0.001). Subsequently, the RTOG (Radiation
Therapy Oncology Group) 91-11 trial10 demonstrated
that concurrent chemoradiotherapy was superior to
IC+RT and RT alone in terms of laryngeal preserva-
tion (88 vs 75 vs 70 per cent, respectively, at three
years), although overall survival in each treatment arm
was similar. Of note, 10-year follow-up data have con-
firmed the superiority of concurrent chemoradiotherapy,
but a significant increase in non-cancer deaths in the
group treated with chemoradiotherapy was reported.11
The use of concurrent chemoradiotherapy for locally
advanced head and neck cancers, including laryngeal
cancers, is also supported by meta-analysis data.12
Standard concurrent chemotherapy regimens include
cisplatin (100 mg/m2) on days 1, 22 and 43 of RT
and carboplatin/5-FU on weeks 1 and 5 of RT.
Concurrent chemoradiotherapy is, however, asso-
ciated with a significant increase in acute and late tox-
icity compared with RT alone. The long-term side
effects of chemoradiotherapy are well documented:
43 per cent of patients develop severe (grade III/IV)
late toxicity, including a reduction in speech and swal-
lowing function which can lead to life-long depend-
ence on a feeding tube (13 per cent of patients two
years after treatment) and have a profound effect on
quality of life (QoL).13 (Although these late severe
toxicities are likely to affect fewer patients when con-
temporary RT delivery schedules are used.) Older
age, advanced T stage, larynx/hypopharynx primary
site and neck dissection after chemoradiotherapy all
increase the risk of severe late toxicity after chemora-
diotherapy and the additional benefit of chemotherapy
must be balanced against the risks for individual
patients. The benefit of chemotherapy decreases with
age and is non-significant above 70 years of age.
Thus, its use may be less appropriate in older patients.
Other systemic therapies that may be given concurrently
with RT include cetuximab, a monoclonal antibody
which competitively inhibits the cell-surface epidermal
growth factor receptor. Cetuximab has been shown to
improve locoregional control (three-year LRC 47 vs
34 per cent, p< 0.01) and overall survival (by 10 per
cent – three-year OS 55 vs 45 per cent) over RT alone
in a study of patients with locally advanced (stage III/
IV) head and neck cancer (27 per cent of whom had
laryngeal cancer). The benefit was maintained on
longer follow-up (five-year OS 46 vs 36 per cent).14
Toxicities of cetuximab include an acneiform rash and
hypersensitivity reactions but it does not increase the
rate of severe radiation-related mucositis. It is an alter-
native to concurrent chemoradiotherapy for patients
with laryngeal cancer who cannot receive concurrent
chemoradiotherapy, as per the guidelines published in
2008 by the National Institute for Health and Care
Excellence (http://www.nice.org.uk/guidance/ta145).
Induction chemotherapy with cisplatin and Q15-FU
(PF) prior to RT may also improve survival,15 but the
benefit of induction chemotherapy prior to standard
concurrent chemoradiotherapy schedules is currently
unproven. If induction chemotherapy is used, taxane
(docetaxel or paclitaxel) in combination with cisplatin
and 5-FU has been shown to be superior to PF
doublet chemotherapy in a meta-analysis of five rando-
mised trials.16
Radiotherapy may be used as a single modality where
comorbidity precludes the use of concurrent chemother-
apy, cetuximab or surgery. Conventional RT alone may
be suboptimal for the treatment of advanced laryngeal
cancer. Altered fractionation regimens (including accel-
eration and hyperfractionation) improve locoregional
control and overall survival compared with standard
fractionated RT for head and neck cancer patients who
elect or are selected to receive RT alone (albeit at the
cost of higher mucosal toxicity).17 However, altered
fractionation regimens do not appear to improve
outcome compared with or when combined with concur-
rent chemoradiotherapy which should be regarded as the
‘standard of care’ for the non-surgical management of
advanced laryngeal cancer. Accelerated fractionation
with hypoxia modification using either nimorazole or
carbogen/nicotinamide shows promising results and
requires further study. To that end, the UK clinical
trial NIMRAD (a randomised placebo-controlled trial
of synchronous NIMorazole vs RADiotherapy alone in
patients with locally advanced head and neck squamous
cell carcinoma not suitable for synchronous chemother-
apy or Cetuximab) (NCT01950689) is currently recruit-
ing in several UK centres.
It is important to note that, despite the laryngeal
preservation and survival rates conferred by non-surgi-
cal strategies, there is a dearth of robust data relating to
laryngeal function after chemoradiotherapy. By com-
parison with non-surgical treatments, any larynx-
preserving surgical procedure – TLM or partial open
procedure – undertaken for T2b/T3 carcinoma of the
larynx will result in dysphonia and prolonged swallow-
ing rehabilitation. Although most patients appear to
achieve satisfactory swallowing function eventually, a
small percentage of patients will require a total laryn-
gectomy for functional reasons.
Whilst TLM or partial open surgical procedures may
be considered as an alternative to non-surgical treatment
for selected cases in appropriate centres, laryngectomy
may be preferred for patients with significant pre-
existing laryngeal destruction by tumour and/or a pre-
treatment tracheostomy; however, reports of whether a
pre-treatment tracheostomy negatively affects outcome
after RT are conflicting and concurrent chemoradiother-
apy remains an option for these patients (25 per cent of
patients in the VALCSG study9 had a baseline tracheos-
tomy and they were not excluded from RTOG 91-11).
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Vocal cord fixation is not a contraindication to larynx
preservation (for either surgical or non-surgical modal-
ities), although it is likely that these patients will have
a poorer functional and oncological outcome than
patients with mobile vocal folds.
In the absence of clinical or radiological evidence of
nodal disease, elective treatment (RT or surgery ±
post-operative RT) is recommended to at least lymph
node levels II, III and IV bilaterally.
Recommendations
• Most patients with T2b–T3 glottic cancers are
suitable for non-surgical larynx preservation
therapies (R)
• Concurrent chemoradiotherapy should be
regarded as the standard of care for non-
surgical management (R)
• Subject to the availability of appropriate
surgical expertise and multi-disciplinary
rehabilitation services, TLM or open partial
surgical procedures ± post-operative RT, may
also be appropriate in selected cases (R)
• In the absence of clinical or radiological
evidence of nodal disease, elective treatment
(RT or surgery ± post-operative RT) is
recommended to at least lymph node levels II,
III and IV bilaterally. In node positive disease,
it is recommended that lymph node levels
II–V should be treated on the involved side. If
level II nodes are involved, then elective
irradiation of ipsilateral level Ib nodes may be
considered (R)
T3 supraglottic carcinoma
The principles of organ preservation for T3 supraglottic
cancers are the same as for glottic cancers. Tumour
size, pre-treatment laryngeal function and performance
status should direct the management of individual
patients. Rates of salvage laryngectomy after surgical
and non-surgical treatment of supraglottic cancers are
lower than for glottic cancers. Vocal cord function is
usually well preserved following TLM or supraglottic
laryngectomy; however, rehabilitation of swallowing
function following supraglottic surgery may be pro-
longed and, whilst most patients achieve satisfactory
swallowing function, this cannot be guaranteed.
T3 supraglottic cancers have a significantly higher
risk of nodal disease (occult and clinical) than glottic
tumours and this must be taken into account when con-
sidering how to manage the neck. In the absence of
clinical or radiological evidence of nodal disease, elect-
ive treatment – RT and/or selective neck dissection –
is recommended to at least lymph node levels II, III, IV
bilaterally.
There is general agreement that chemoradiotherapy
is sufficient to treat early nodal disease (N1, single
lymph node <3 cm) in patients with glottic cancers.
Since publication of the last edition, management of
N2 (multiple lymph nodes and/or >3–6 cm) or N3
(>6 cm) nodal disease has been informed by the
PET-Neck clinical trial.18 The data confirm that posi-
tron emission tomography combined with computed
tomography (PET–CT) surveillance of the neck in che-
moradiotherapy complete responders, obviates the
need for an elective neck dissection in patients with a
negative PET–CT scan result.
Recommendations
• Most patients with T3 supraglottic cancers
are suitable for non-surgical larynx
preservation therapies (R)
• Concurrent chemoradiotherapy should be
regarded as the standard of care for non-
surgical management (R)
• Subject to the availability of appropriate
surgical expertise and multi-disciplinary
rehabilitation services, TLM or open partial
surgical procedures ± post-operative RT, may
also be appropriate in selected cases (R)
• In the absence of clinical or radiological
evidence of nodal disease, elective treatment
(RT or surgery ± post-operative RT) is
recommended to at least lymph node levels II,
III and IV bilaterally. In node positive disease,
lymph node levels II–V should be treated on
the involved side (R)
• As per the PET-Neck clinical trial, patients with
N2 or N3 neck disease who undergo treatment
with chemoradiotherapy to their laryngeal
primary and experience a complete response
with a subsequent negative post-treatment
PET–CT scan do not require planned neck
dissection. In contrast, patients who have a
partial response to treatment or have increased
uptake on a post-treatment PET–CT scan
should have a neck dissection (R)
T4 laryngeal carcinoma
Larynx preservation with chemoradiotherapy should be
considered for T4 tumours, unless there is tumour inva-
sion through cartilage into the soft tissues of the neck,
in which total laryngectomy followed by adjuvant treat-
ment yields better outcomes. The VALCSG study9
showed reduced tumour response to chemotherapy
and higher rates of salvage laryngectomy for T4
tumours (56 per cent for T4 vs 29 per cent for T3
tumours, p= 0.001). Nevertheless, larynx preservation
can be achieved in a significant proportion of patients
with T4 disease, without detriment to survival when
salvage laryngectomy is incorporated. However, once
again, few data are available correlating laryngeal
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preservation with function and QoL. Good patient
selection is of paramount importance. Patients with
large-volume T4 tumours – defined as extension of
tumour through thyroid cartilage or tumour extension
greater than 1 cm into the base of tongue – were
excluded from RTOG 91-1110 as they are poor candi-
dates for organ preservation. Patients with significant
pre-existing laryngeal destruction by tumour and/or a
pre-treatment tracheostomy may also be better suited
to a total laryngectomy. Total laryngectomy may
confer a better QoL than a preserved, but poorly func-
tioning, larynx.
Patients with large-volume T4 tumours who are
unsuitable for surgery because of inoperable (T4b)
disease have been treated with combined-modality
organ preservation therapy with significant rates of
disease control (71 per cent at four years) and overall
survival (56 per cent at four years) in retrospective
studies. Induction chemotherapy may be used to treat
large volume, symptomatic disease prior to commence-
ment of concurrent chemoradiotherapy.
Lymph node levels II–V bilaterally should be
treated, irrespective of the pre-treatment clinical nodal
status. As per the findings of the PET-Neck trial18
(see above), a planned neck dissection is not necessary
in patients who experience a complete response to che-
moradiotherapy and have a post-treatment negative
PET–CT scan. Improved systemic therapies and RT
dose intensification using IMRT may improve out-
comes for this patient group in future.
Recommendations
• Larynx preservation with concurrent
chemoradiotherapy should be considered for
T4 tumours, unless there is tumour invasion
through cartilage into the soft tissues of the
neck, in which case total laryngectomy yields
better outcomes (R)
• In the absence of clinical or radiological
evidence of nodal disease, elective treatment
(RT or surgery ± post-operative RT) is
recommended to bilateral lymph node levels
II, III, IV, V and VI (R)
Post-operative RT /chemoradiotherapy
Radiotherapy delivered post-operatively to the primary
site and/or neck in patients at high risk of locoregional
recurrence can improve locoregional control and sur-
vival. Post-operative RT is recommended for pT4 laryn-
geal cancers of any nodal stage, pT1/T2/T3 tumours
with N2–N3 nodal stage and for all patients with close
or positive resection margins and/or extracapsular
spread; other unfavourable pathological factors, includ-
ing peri-neurial and vascular invasion, are relative indica-
tions for post-operative RT. Administration of concurrent
cisplatin chemotherapy with post-operative RT improves
locoregional control and disease-free survival compared
with post-operative RT alone for locally advanced
tumours,19,20 albeit at the expense of increased mucosal
and haematological toxicity and possibly increased
deaths. This approach improves overall survival in
selected patients, particularly with extracapsular spread
and/or positive margins, and should be used selectively
for patients at highest risk of relapse.
Key points
• Approximately 2400 patients are diagnosed with
laryngeal squamous cell carcinoma and ∼800
patients die of the disease per annum in the UK
• Early stage tumours of the glottis present with
hoarseness, whilst tumours of the supraglottis and
more advanced glottic tumours may present with
pain, odynophagia and/or dysphagia, a neck lump
or even airway compromise
• Meticulous endoscopic inspection of the tumour
under general anaesthetic and imaging of the head,
neck and thorax is needed for staging
• Radiotherapy and transoral laser microsurgery are
reasonable treatment options for T1a–T2a glottic
and T1–T2 supraglottic carcinomas
• Most patients with T2b–T3 glottic and T3 supraglot-
tic cancers are suitable for non-surgical larynx pres-
ervation therapies. Transoral laser microsurgery or
open partial surgical procedures ± post-operative
radiotherapy may be also be appropriate in selected
cases
• Concurrent chemoradiotherapy should be regarded
as standard of care for the non-surgical management
of stage III/IV laryngeal cancer
• Patients with N2 or N3 neck disease who experience a
complete response with a subsequent negative post-
treatment PET–CT scan do not require planned
neck dissection
• Post-operative (chemo)radiotherapy is recommended
in the presence of advanced disease or adverse histo-
logical features.
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